Narriane Chaves Pereira de Holanda
Research Subjects
Narriane Chaves Pereira de Holanda has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Francisco Bandeira
Division of Endocrinology and Diabetes, Agamenon Magalhães Hospital, Faculty of Medical Sciences, University of Pernambuco (UPE), Recife, Brazil
6 shared publications - Caio Chaves de Holanda Limeira
Faculdade de Medicina Nova Esperança
4 shared publications - Bruno Leandro de Souza
Conselho Federal de Medicina
3 shared publications - Heloísa Calegari Borges
Faculdade de Medicina Nova Esperança
3 shared publications Ana Carla Peres Montenegro
Instituto de Medicina Integral de Pernambuco - IMIP, Recife, Brazil
2 shared publications- Francisco José Albuquerque de Paula
Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista Bioética
- Vol. 34
Incretinomiméticos sob olhar bioético: entre terapêutica, estética e justiça sanitária
Resumo Os incretinomiméticos agonistas do receptor de GLP-1 e agonistas duais GIP/GLP-1 redefiniram o tratamento do diabetes tipo 2 e da obesidade por associarem controle glicêmico, perda ponderal e benefícios cardiovasculares em contextos selecionados. Articulando o principialismo bioético a perspectivas críticas contemporâneas, incluindo bioética de intervenção, justiça sanitária, medicalização e mercantilização do cuidado, esta revisão narrativa sistematizada analisou fundamentos farmacológicos, eficácia, segurança e desafios regulatórios, econômicos e distributivos dessas terapias. Discutem-se as tensões entre uso terapêutico e estético, risco de medicalização do emagrecimento, barreiras de acesso e impactos sobre a sustentabilidade dos sistemas de saúde. Conclui-se que a incorporação eticamente defensável dos incretinomiméticos exige prudência clínica, consentimento esclarecido, acompanhamento longitudinal, critérios transparentes de priorização e compromisso com equidade, continuidade do cuidado e proteção contra desigualdades globais de acesso a inovações farmacológicas.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista Bioética
- Vol. 34
Open AccessIncretinomiméticos sob olhar bioético: entre terapêutica, estética e justiça sanitária
Resumo Os incretinomiméticos agonistas do receptor de GLP-1 e agonistas duais GIP/GLP-1 redefiniram o tratamento do diabetes tipo 2 e da obesidade por associarem controle glicêmico, perda ponderal e benefícios cardiovasculares em contextos selecionados. Articulando o principialismo bioético a perspectivas críticas contemporâneas, incluindo bioética de intervenção, justiça sanitária, medicalização e mercantilização do cuidado, esta revisão narrativa sistematizada analisou fundamentos farmacológicos, eficácia, segurança e desafios regulatórios, econômicos e distributivos dessas terapias. Discutem-se as tensões entre uso terapêutico e estético, risco de medicalização do emagrecimento, barreiras de acesso e impactos sobre a sustentabilidade dos sistemas de saúde. Conclui-se que a incorporação eticamente defensável dos incretinomiméticos exige prudência clínica, consentimento esclarecido, acompanhamento longitudinal, critérios transparentes de priorização e compromisso com equidade, continuidade do cuidado e proteção contra desigualdades globais de acesso a inovações farmacológicas.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista Bioética
- Vol. 34
Incretinomiméticos bajo mirada bioética: entre terapéutica, estética y justicia sanitaria
Resumen Los incretinomiméticos agonistas del receptor de GLP-1 y agonistas duales GIP/GLP-1 han redefinido el tratamiento de la diabetes tipo 2 y la obesidad, asociando control glucémico, pérdida de peso y beneficios cardiovasculares en contextos seleccionados. Esta revisión narrativa sistematizada analizó fundamentos farmacológicos, eficacia, seguridad y desafíos regulatorios, económicos y distributivos de estas terapias, articulando el principialismo bioético con perspectivas críticas contemporáneas, incluyendo bioética de intervención, justicia sanitaria, medicalización y mercantilización del cuidado. Se discuten las tensiones entre uso terapéutico y estético, el riesgo de medicalización del adelgazamiento, las barreras de acceso y los impactos sobre la sostenibilidad de los sistemas de salud. Se concluye que la incorporación éticamente defendible de los incretinomiméticos exige prudencia clínica, consentimiento informado, seguimiento longitudinal, criterios transparentes de priorización y compromiso con equidad, continuidad del cuidado y protección frente a desigualdades globales de acceso a innovaciones farmacológicas.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista Bioética
- Vol. 34
Open AccessIncretinomiméticos bajo mirada bioética: entre terapéutica, estética y justicia sanitaria
Resumen Los incretinomiméticos agonistas del receptor de GLP-1 y agonistas duales GIP/GLP-1 han redefinido el tratamiento de la diabetes tipo 2 y la obesidad, asociando control glucémico, pérdida de peso y beneficios cardiovasculares en contextos seleccionados. Esta revisión narrativa sistematizada analizó fundamentos farmacológicos, eficacia, seguridad y desafíos regulatorios, económicos y distributivos de estas terapias, articulando el principialismo bioético con perspectivas críticas contemporáneas, incluyendo bioética de intervención, justicia sanitaria, medicalización y mercantilización del cuidado. Se discuten las tensiones entre uso terapéutico y estético, el riesgo de medicalización del adelgazamiento, las barreras de acceso y los impactos sobre la sostenibilidad de los sistemas de salud. Se concluye que la incorporación éticamente defendible de los incretinomiméticos exige prudencia clínica, consentimiento informado, seguimiento longitudinal, criterios transparentes de priorización y compromiso con equidad, continuidad del cuidado y protección frente a desigualdades globales de acceso a innovaciones farmacológicas.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista Bioética
- Vol. 34
Incretinomimetics under a bioethical lens: between therapeutics, aesthetics and health justice
GLP-1 receptor agonists and dual GIP/GLP-1 incretinomimetics have redefined the treatment of type 2 diabetes and obesity by combining glycemic control, weight loss, and cardiovascular benefits in selected settings. This systematized narrative review analyzed pharmacological foundations, efficacy, safety, and regulatory, economic, and distributive challenges of these therapies, articulating bioethical principlism with contemporary critical perspectives, including intervention bioethics, health justice, medicalization, and commodification of care. The review discusses tensions between therapeutic and aesthetic use, the risk of medicalizing weight loss, barriers to access, and impacts on health system sustainability. It concludes that the ethically defensible incorporation of incretinomimetics requires clinical prudence, informed consent, longitudinal follow-up, transparent prioritization criteria, and a commitment to equity, continuity of care, and protection against global inequalities in access to pharmacological innovations.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista Bioética
- Vol. 34
Open AccessIncretinomimetics under a bioethical lens: between therapeutics, aesthetics and health justice
GLP-1 receptor agonists and dual GIP/GLP-1 incretinomimetics have redefined the treatment of type 2 diabetes and obesity by combining glycemic control, weight loss, and cardiovascular benefits in selected settings. This systematized narrative review analyzed pharmacological foundations, efficacy, safety, and regulatory, economic, and distributive challenges of these therapies, articulating bioethical principlism with contemporary critical perspectives, including intervention bioethics, health justice, medicalization, and commodification of care. The review discusses tensions between therapeutic and aesthetic use, the risk of medicalizing weight loss, barriers to access, and impacts on health system sustainability. It concludes that the ethically defensible incorporation of incretinomimetics requires clinical prudence, informed consent, longitudinal follow-up, transparent prioritization criteria, and a commitment to equity, continuity of care, and protection against global inequalities in access to pharmacological innovations.
- 29 January 2024
- Published by Springer Nature in Obesity Surgery
- Vol. 34 (3) , 733-740
Prevalence of Morphometric Vertebral Fractures After Bariatric Surgery and Its Relationship with Bone Mineral Density and Bone Markers
Background Bariatric surgery (BS) can lead to bone loss and an increased fracture risk. Methods To determine the morphometric vertebral fracture (MVF) prevalence, and its relationship with bone mineral density (BMD), and biomarker’s turnover after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG), we analyzed post-surgery X-rays of the spine in 80 patients (88% female, 51% RYGB, age 41.2 [6.8] years) from 117 participants’ retrospective cohort (1–2 years, >2 and 5 years). We still analyzed body composition and BMD by dual-energy X-ray absorptiometry and bone parameters. Results MVF prevalence was 17.5% (14/80), with no statistical difference between groups (p = 0.210). RYGB group had a higher prevalence of secondary hyperparathyroidism (SHPT) (PTH ≥ 65 pg/ml; 18.4% vs 7.8%, respectively, p = 0.04), PTH (61.3 vs 49.5 pg/ml, p = 0.001), CTX (0.766 [0.29] ng/ml vs 0.453 [0.30] ng/ml, p = 0.037), and AP (101.3 [62.4] U/L vs 123.9 [60.9] U/L, p = 0.027) than the SG group. Up to 5 years postoperatively, RYGB had a lower total (1.200 [0.087] vs 1.236 [0.100] g/cm2, p = 0.02), femoral neck (1.034 [0.110] vs 1.267 [0.105], p = 0.005), and total femur BMD (1.256 [0.155] vs 1.323 [0.167], p = 0.002) than SG group. We found no statistically significant difference between the MFV (+) and MVF (−) groups regarding age, sex, BMI, surgery time, BMD, or bone and metabolic parameters, including leptin. Conclusion We found a high prevalence of MVF after BS with no differences between RYGB and SG. Graphical Abstract
- 29 January 2024
- Published by Springer Nature in Obesity Surgery
- Vol. 34 (3) , 733-740
Prevalence of Morphometric Vertebral Fractures After Bariatric Surgery and Its Relationship with Bone Mineral Density and Bone Markers
Background Bariatric surgery (BS) can lead to bone loss and an increased fracture risk. Methods To determine the morphometric vertebral fracture (MVF) prevalence, and its relationship with bone mineral density (BMD), and biomarker’s turnover after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG), we analyzed post-surgery X-rays of the spine in 80 patients (88% female, 51% RYGB, age 41.2 [6.8] years) from 117 participants’ retrospective cohort (1–2 years, >2 and 5 years). We still analyzed body composition and BMD by dual-energy X-ray absorptiometry and bone parameters. Results MVF prevalence was 17.5% (14/80), with no statistical difference between groups (p = 0.210). RYGB group had a higher prevalence of secondary hyperparathyroidism (SHPT) (PTH ≥ 65 pg/ml; 18.4% vs 7.8%, respectively, p = 0.04), PTH (61.3 vs 49.5 pg/ml, p = 0.001), CTX (0.766 [0.29] ng/ml vs 0.453 [0.30] ng/ml, p = 0.037), and AP (101.3 [62.4] U/L vs 123.9 [60.9] U/L, p = 0.027) than the SG group. Up to 5 years postoperatively, RYGB had a lower total (1.200 [0.087] vs 1.236 [0.100] g/cm2, p = 0.02), femoral neck (1.034 [0.110] vs 1.267 [0.105], p = 0.005), and total femur BMD (1.256 [0.155] vs 1.323 [0.167], p = 0.002) than SG group. We found no statistically significant difference between the MFV (+) and MVF (−) groups regarding age, sex, BMI, surgery time, BMD, or bone and metabolic parameters, including leptin. Conclusion We found a high prevalence of MVF after BS with no differences between RYGB and SG. Graphical Abstract
- Open Access
- 20 September 2023
- Published by Wiley in Journal of Obesity
- Vol. 2023, 1-6
Vitamin D Concentration Changes after Bariatric Surgery
Introduction. Bariatric surgery causes physiological and anatomical changes in the gastrointestinal tract that interfere with intestinal absorption and, consequently, with the nutritional status, especially about vitamin D. The aim of the study was to evaluate the vitamin D levels and body composition of these patients in the Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG) types of surgery. Methods. The retrospective cohort study included a population of 120 patients aged between 18 and 65years, with class II or III obesity, undergoing bariatric surgery procedures (VSG or RYGB-type). Data were collected on the degree of obesity, age, average time since surgery, and gender. The individuals underwent a complete physical examination, measuring blood pressure, weight, height, waist, and neck circumference. In addition to calculating the percentage of loss of body weight and assessing body fat, the food frequency and physical activity of these patients were evaluated. Blood was collected, and the insulin variables, hydroxyvitamin D (25OHD), were analyzed. Results. There was a significant difference between groups only for PTH, total BMD, and insulin variables. A significant intragroup difference was found in the variables body mass index (BMI) and vitamin D for the vertical sleeve gastrectomy group and BMI for the RYGB group. Conclusion. The analysis between the groups of procedures, similarity in body composition and postsurgical vitamin D levels, with significant differences only for PTH, BMD, and insulin variables, demonstrates that both procedures are effective in reducing fat mass.
- 20 September 2023
- Published by Wiley in Journal of Obesity
- Vol. 2023, 1-6
Open AccessVitamin D Concentration Changes after Bariatric Surgery
Introduction. Bariatric surgery causes physiological and anatomical changes in the gastrointestinal tract that interfere with intestinal absorption and, consequently, with the nutritional status, especially about vitamin D. The aim of the study was to evaluate the vitamin D levels and body composition of these patients in the Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG) types of surgery. Methods. The retrospective cohort study included a population of 120 patients aged between 18 and 65years, with class II or III obesity, undergoing bariatric surgery procedures (VSG or RYGB-type). Data were collected on the degree of obesity, age, average time since surgery, and gender. The individuals underwent a complete physical examination, measuring blood pressure, weight, height, waist, and neck circumference. In addition to calculating the percentage of loss of body weight and assessing body fat, the food frequency and physical activity of these patients were evaluated. Blood was collected, and the insulin variables, hydroxyvitamin D (25OHD), were analyzed. Results. There was a significant difference between groups only for PTH, total BMD, and insulin variables. A significant intragroup difference was found in the variables body mass index (BMI) and vitamin D for the vertical sleeve gastrectomy group and BMI for the RYGB group. Conclusion. The analysis between the groups of procedures, similarity in body composition and postsurgical vitamin D levels, with significant differences only for PTH, BMD, and insulin variables, demonstrates that both procedures are effective in reducing fat mass.
- Open Access
- 16 November 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 66 (5) , 621-632
Musculoskeletal effects of obesity and bariatric surgery – a narrative review
Obesity affects several areas of the human body, leading to increased morbidity and mortality and the likelihood of other diseases, such as type 2 diabetes mellitus, cardiovascular diseases and musculoskeletal disorders. These conditions predispose to bone fractures and sarcopenic obesity, defined by the presence of an obesity-associated decrease in muscle mass and strength. Both bone fragility and sarcopenic obesity disease are consequences of several factors, such as a low degree of chronic inflammation, insulin resistance, hormonal changes, nutritional deficiencies, [...] Abstract Obesity affects several areas of the human body, leading to increased morbidity and mortality and the likelihood of other diseases, such as type 2 diabetes mellitus, cardiovascular diseases and musculoskeletal disorders. These conditions predispose to bone fractures and sarcopenic obesity, defined by the presence of an obesity-associated decrease in muscle mass and strength. Both bone fragility and sarcopenic obesity disease are consequences of several factors, such as a low degree of chronic inflammation, insulin resistance, hormonal changes, nutritional deficiencies,
- 16 November 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 66 (5) , 621-632
Open AccessMusculoskeletal effects of obesity and bariatric surgery – a narrative review
Obesity affects several areas of the human body, leading to increased morbidity and mortality and the likelihood of other diseases, such as type 2 diabetes mellitus, cardiovascular diseases and musculoskeletal disorders. These conditions predispose to bone fractures and sarcopenic obesity, defined by the presence of an obesity-associated decrease in muscle mass and strength. Both bone fragility and sarcopenic obesity disease are consequences of several factors, such as a low degree of chronic inflammation, insulin resistance, hormonal changes, nutritional deficiencies, [...] Abstract Obesity affects several areas of the human body, leading to increased morbidity and mortality and the likelihood of other diseases, such as type 2 diabetes mellitus, cardiovascular diseases and musculoskeletal disorders. These conditions predispose to bone fractures and sarcopenic obesity, defined by the presence of an obesity-associated decrease in muscle mass and strength. Both bone fragility and sarcopenic obesity disease are consequences of several factors, such as a low degree of chronic inflammation, insulin resistance, hormonal changes, nutritional deficiencies,
- 20 October 2022
- Published by Even3
Guia Prático em Osteometabolismo
A relevância e a abordagem consistente dos temas reunidos no Guia Prático em Osteometabolismo asseguraram a publicação dessa nova edição. Preparada pelos membros do Departamento de Metabolismo Ósseo e Mineral da Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) e por seus colaboradores, oferece uma visão ainda mais detalhada sobre condições enfrentadas diariamente por clínicos e especialistas, como diabetes mellitus, osteoporose, hipertireoidismo e hipoparatireoidismo. Com isso, o guia mantém a sua condição como material de consulta e referência para profissionais da Endocrinologia e áreas relacionadas.
- 20 October 2022
- Published by Even3
Guia Prático em Osteometabolismo
A relevância e a abordagem consistente dos temas reunidos no Guia Prático em Osteometabolismo asseguraram a publicação dessa nova edição. Preparada pelos membros do Departamento de Metabolismo Ósseo e Mineral da Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) e por seus colaboradores, oferece uma visão ainda mais detalhada sobre condições enfrentadas diariamente por clínicos e especialistas, como diabetes mellitus, osteoporose, hipertireoidismo e hipoparatireoidismo. Com isso, o guia mantém a sua condição como material de consulta e referência para profissionais da Endocrinologia e áreas relacionadas.
- Open Access
- 3 October 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 66 (5) , 591-603
Definition and management of very high fracture risk in women with postmenopausal osteoporosis: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Association of Bone Assessment and Metabolism (ABRASSO)
Several drugs are available for the treatment of osteoporosis in postmenopausal women. Over the last decades, most patients requiring pharmacological intervention were offered antiresorptive drugs as first-line therapy, while anabolic agents were considered a last resource for those with therapeutic failure. However, recent randomized trials in patients with severe osteoporosis have shown that anabolic agents reduce fractures to a greater extent than antiresorptive medications. Additionally, evidence indicates that increases in bone mineral density (BMD) are maximized when patients are [...] ABSTRACT Several drugs are available for the treatment of osteoporosis in postmenopausal women. Over the last decades, most patients requiring pharmacological intervention were offered antiresorptive drugs as first-line therapy, while anabolic agents were considered a last resource for those with therapeutic failure. However, recent randomized trials in patients with severe osteoporosis have shown that anabolic agents reduce fractures to a greater extent than antiresorptive medications. Additionally, evidence indicates that increases in bone mineral density (BMD) are maximized when patients are
- 3 October 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 66 (5) , 591-603
Open AccessDefinition and management of very high fracture risk in women with postmenopausal osteoporosis: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Association of Bone Assessment and Metabolism (ABRASSO)
Several drugs are available for the treatment of osteoporosis in postmenopausal women. Over the last decades, most patients requiring pharmacological intervention were offered antiresorptive drugs as first-line therapy, while anabolic agents were considered a last resource for those with therapeutic failure. However, recent randomized trials in patients with severe osteoporosis have shown that anabolic agents reduce fractures to a greater extent than antiresorptive medications. Additionally, evidence indicates that increases in bone mineral density (BMD) are maximized when patients are [...] ABSTRACT Several drugs are available for the treatment of osteoporosis in postmenopausal women. Over the last decades, most patients requiring pharmacological intervention were offered antiresorptive drugs as first-line therapy, while anabolic agents were considered a last resource for those with therapeutic failure. However, recent randomized trials in patients with severe osteoporosis have shown that anabolic agents reduce fractures to a greater extent than antiresorptive medications. Additionally, evidence indicates that increases in bone mineral density (BMD) are maximized when patients are
- 1 January 2022
- Published by Elsevier in Endocrine Practice
- Vol. 28 (1) , 58-69
Fracture Risk After Bariatric Surgery: A Systematic Literature Review and Meta-Analysis
- 1 January 2022
- Published by Elsevier in Endocrine Practice
- Vol. 28 (1) , 58-69
Fracture Risk After Bariatric Surgery: A Systematic Literature Review and Meta-Analysis
- 12 October 2021
- Published by Springer Nature in Obesity Surgery
- Vol. 31 (12) , 5367-5375
Secondary Hyperparathyroidism, Bone Density, and Bone Turnover After Bariatric Surgery: Differences Between Roux-en-Y Gastric Bypass and Sleeve Gastrectomy
Purpose Bariatric surgery may lead to metabolic bone disease. Materials and Methods In this cross-sectional study, we compared the prevalence of secondary hyperparathyroidism (SHPT), impact on bone mass and turnover markers, and serum leptin after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) in 117 patients (91% female, 51% RYGB, age 41.8 ± 6.7 years, time of surgery 4.3 ± 3.4 years) at different times (1–2 years, > 2 and < 5 years and ≥ 5 years). Body composition, bone mineral density (BMD), by dual-energy X-ray absorptiometry, and bone parameters (PTH, serum calcium, 25OHD, alkaline phosphatase (AP), C-telopeptide (CTX)) were analyzed. Results Prevalence of SHPT (PTH ≥ 65 pg/ml) was 26%, RYGB > SG (18.4% vs. 7.8%, p = 0.039), despite similar 25OHD and calcium levels. Mean PTH, CTX, and AP were higher in RYGB vs. SG (61.3 ± 29.5 vs 49.5 ± 32.3 pg/ml, p = 0.001; 0.596 ± 0.24 vs. 0.463 ± 0.23 ng/ml; 123.9 ± 60.8 vs. 100.7 ± 62.0 U/l). There were 13.5% decreases in femoral neck BMD in all patients, over the study period. In the last group, the RYGB group showed greater bone loss in total body BMD (1.016 vs. 1.151 g/cm2, − 8.1%, p = 0.003) and total femur BMD (1.164 vs. 1.267 g/cm2, − 11.7%, p = 0.007). Mean leptin was lower in the RYGB vs. SG group, with no correlation with BMD in any site. Conclusion Our data suggest a more deleterious role of RYGB on bone remodeling up to 5 years postoperatively in comparison with SG. Graphical abstract
- 12 October 2021
- Published by Springer Nature in Obesity Surgery
- Vol. 31 (12) , 5367-5375
Secondary Hyperparathyroidism, Bone Density, and Bone Turnover After Bariatric Surgery: Differences Between Roux-en-Y Gastric Bypass and Sleeve Gastrectomy
Purpose Bariatric surgery may lead to metabolic bone disease. Materials and Methods In this cross-sectional study, we compared the prevalence of secondary hyperparathyroidism (SHPT), impact on bone mass and turnover markers, and serum leptin after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) in 117 patients (91% female, 51% RYGB, age 41.8 ± 6.7 years, time of surgery 4.3 ± 3.4 years) at different times (1–2 years, > 2 and < 5 years and ≥ 5 years). Body composition, bone mineral density (BMD), by dual-energy X-ray absorptiometry, and bone parameters (PTH, serum calcium, 25OHD, alkaline phosphatase (AP), C-telopeptide (CTX)) were analyzed. Results Prevalence of SHPT (PTH ≥ 65 pg/ml) was 26%, RYGB > SG (18.4% vs. 7.8%, p = 0.039), despite similar 25OHD and calcium levels. Mean PTH, CTX, and AP were higher in RYGB vs. SG (61.3 ± 29.5 vs 49.5 ± 32.3 pg/ml, p = 0.001; 0.596 ± 0.24 vs. 0.463 ± 0.23 ng/ml; 123.9 ± 60.8 vs. 100.7 ± 62.0 U/l). There were 13.5% decreases in femoral neck BMD in all patients, over the study period. In the last group, the RYGB group showed greater bone loss in total body BMD (1.016 vs. 1.151 g/cm2, − 8.1%, p = 0.003) and total femur BMD (1.164 vs. 1.267 g/cm2, − 11.7%, p = 0.007). Mean leptin was lower in the RYGB vs. SG group, with no correlation with BMD in any site. Conclusion Our data suggest a more deleterious role of RYGB on bone remodeling up to 5 years postoperatively in comparison with SG. Graphical abstract